Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

2nd November 2018 Uncategorised 0

Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win that could give sales a leg up.

More: Celgene lines up for 0M Revlimid boost as Rituxan combo scores in lymphoma
Source: fierce